- Home
- MNPR vs BDN Comparison
MNPR vs BDN Comparison
Compare MNPR & BDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- BDN
- Stock Information
- Founded
- MNPR 2014
- BDN 1986
- Country
- MNPR United States
- BDN United States
- Employees
- MNPR N/A
- BDN N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- BDN Real Estate Investment Trusts
- Sector
- MNPR Health Care
- BDN Real Estate
- Exchange
- MNPR Nasdaq
- BDN Nasdaq
- Market Cap
- MNPR 531.6M
- BDN 588.8M
- IPO Year
- MNPR 2019
- BDN N/A
- Fundamental
- Price
- MNPR $92.78
- BDN $3.46
- Analyst Decision
- MNPR Strong Buy
- BDN Hold
- Analyst Count
- MNPR 13
- BDN 2
- Target Price
- MNPR $97.83
- BDN $4.00
- AVG Volume (30 Days)
- MNPR 161.9K
- BDN 2.7M
- Earning Date
- MNPR 11-13-2025
- BDN 10-22-2025
- Dividend Yield
- MNPR N/A
- BDN 9.28%
- EPS Growth
- MNPR N/A
- BDN N/A
- EPS
- MNPR N/A
- BDN N/A
- Revenue
- MNPR N/A
- BDN $403,561,000.00
- Revenue This Year
- MNPR N/A
- BDN $58.99
- Revenue Next Year
- MNPR N/A
- BDN $0.33
- P/E Ratio
- MNPR N/A
- BDN N/A
- Revenue Growth
- MNPR N/A
- BDN 31.34
- 52 Week Low
- MNPR $18.67
- BDN $3.23
- 52 Week High
- MNPR $105.00
- BDN $5.90
- Technical
- Relative Strength Index (RSI)
- MNPR 64.12
- BDN 45.43
- Support Level
- MNPR $74.58
- BDN $3.33
- Resistance Level
- MNPR $84.06
- BDN $3.52
- Average True Range (ATR)
- MNPR 6.71
- BDN 0.11
- MACD
- MNPR 0.32
- BDN 0.03
- Stochastic Oscillator
- MNPR 95.22
- BDN 71.43
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About BDN Brandywine Realty Trust
Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.